DNA DAMAGE RESPONSE TARGETING THERAPEUTICS (BEYOND PARP INHIBITORS) - CURRENT MARKET LANDSCAPE
During our research, we came across over 43 companies that are presently engaged in the development of DDR targeting therapeutics.
There has been a significant increase in the number of developers that have been established in this domain post-2008. In fact, close to XX players were established during the period 2013-2016. Further, over XX developers have been founded since 2017.
To order...
0 Comments
0 Shares
Please log in to like, share and comment!
Sponsorship